2024
Severe Sepsis During Treatment for Childhood Leukemia and Sequelae Among Adult Survivors
Goggin K, Lu L, Lee D, Howell C, Srivastava D, Brinkman T, Armstrong G, Bhakta N, Robison L, Ehrhardt M, Hudson M, Krull K, Pui C, Rubnitz J, Ness K, Wolf J. Severe Sepsis During Treatment for Childhood Leukemia and Sequelae Among Adult Survivors. JAMA Network Open 2024, 7: e242727. PMID: 38497960, PMCID: PMC10949094, DOI: 10.1001/jamanetworkopen.2024.2727.Peer-Reviewed Original ResearchConceptsChronic health conditionsHealth conditionsAdult survivorsCohort studyAdult survivors of childhood cancerSt Jude Lifetime Cohort StudyIncidence of chronic health conditionsChildhood leukemiaSurvivors of childhood cancerAssociated with long-term riskIncreased riskMedical record reviewQuality of lifeInverse propensity score weightingAdult survivors of childhood leukemiaYear of diagnosisCancer survivorsSevere sepsisPropensity score weightingSurvivors of childhood leukemiaMain OutcomesPotential confoundersChildhood cancerRecord reviewLong-term risk
2008
TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival
Mu L, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Yu H. TGF-β1 genotype and phenotype in breast cancer and their associations with IGFs and patient survival. British Journal Of Cancer 2008, 99: 1357-1363. PMID: 18827819, PMCID: PMC2570529, DOI: 10.1038/sj.bjc.6604689.Peer-Reviewed Original ResearchConceptsHigher TGF-β1TGF-β1 genotypesTGF-β1T genotypeHazard ratioBreast cancerBreast tumorsProportional hazards regression analysisLower TGF-β1Early-stage diseaseHazards regression analysisBreast cancer patientsLate-stage diseaseShorter overall survivalFresh tumor samplesTGF-β1 concentrationsBreast cancer progressionClinical characteristicsIGFBP-3Overall survivalDisease recurrenceReceptor statusPatient survivalSurvival outcomesDisease stageKlotho Expression in Epithelial Ovarian Cancer and its Association with Insulin-Like Growth Factors and Disease Progression
Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H. Klotho Expression in Epithelial Ovarian Cancer and its Association with Insulin-Like Growth Factors and Disease Progression. Cancer Investigation 2008, 26: 185-192. PMID: 18259951, DOI: 10.1080/07357900701638343.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCystadenocarcinoma, SerousDisease ProgressionEpithelial CellsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGlucuronidaseHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IIKlotho ProteinsMiddle AgedNeoplasm StagingOvarian NeoplasmsPrognosisReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmSurvival RateConceptsEpithelial ovarian cancerKlotho expressionOvarian cancer progressionDisease progressionOvarian cancerCox proportional hazards regression modelTumor tissueProportional hazards regression modelsCancer progressionInsulin-like growth factorResidual tumor sizeAction of IGFOvarian cancer patientsExpression of IGFHazards regression modelsOvarian cancer prognosisEpithelial ovarian cancer progressionExpression of totalFresh tumor tissueWarrants further elucidationUnderwent surgeryIGFBP-3Patient ageClinical followTumor histology
2007
Expression of MDR1 in epithelial ovarian cancer and its association with disease progression.
Lu L, Katsaros D, Wiley A, Rigault de la Longrais IA, Puopolo M, Yu H. Expression of MDR1 in epithelial ovarian cancer and its association with disease progression. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 2007, 16: 395-403. PMID: 17913048, DOI: 10.3727/000000006783980892.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsATP Binding Cassette Transporter, Subfamily B, Member 1Biomarkers, TumorBRCA1 ProteinCyclin-Dependent Kinase Inhibitor p16Disease ProgressionDrug Resistance, MultipleEstrogen Receptor alphaFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousOvarian NeoplasmsPrognosisRetrospective StudiesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerRNA, NeoplasmSurvival AnalysisTreatment OutcomeConceptsMDR1 expressionClinicopathological parametersDisease progressionOvarian cancer cohortEpithelial ovarian cancerOvarian cancer prognosisOvarian cancer treatmentOvarian cancer progressionExpression of MDR1Ovarian tumor samplesOverall survivalPatient ageOvarian tumorsIGF-IIQuantitative real-time PCROvarian cancerCancer cohortReal-time PCRIndependent markerCancer prognosisDrug resistanceTumor samplesCancer treatmentCancer progressionERalphaIGF-I in epithelial ovarian cancer and its role in disease progression
Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H, Yu H. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007, 25: 346-354. PMID: 18236213, DOI: 10.1080/08977190701838402.Peer-Reviewed Original ResearchConceptsIGF-I transcriptsDisease progressionOvarian cancerTumor progressionEpithelial ovarian cancer patientsIGF-I mRNA expressionInsulin-like growth factorParacrine/autocrine regulationIGF-I activityEpithelial ovarian cancerIGF-I actionOvarian cancer patientsFresh tumor samplesIGF-I expressionIGF-I mRNAOvarian cancer progressionEnzyme-linked immunosorbentParacrine/autocrineTotal IGFFree IGFClinicopathologic featuresCA polymorphismCancer patientsReal-time PCRElevated risk
2006
Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer
Lu L, Katsaros D, Wiley A, de la Longrais I, Puopolo M, Schwartz P, Yu H. Promoter-specific transcription of insulin-like growth factor-II in epithelial ovarian cancer. Gynecologic Oncology 2006, 103: 990-995. PMID: 16859738, DOI: 10.1016/j.ygyno.2006.06.006.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDisease ProgressionDNA PrimersFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionRNA, MessengerConceptsIGF-II promotersResidual tumorOvarian cancerIGF-II transcriptionNon-serous histologyInsulin-like growth factor IISmall residual tumorLarge residual tumorLate-stage diseaseEpithelial ovarian cancerOvarian cancer prognosisOvarian cancer progressionOvarian tumor samplesGrowth factor IIIGF-II geneOptimal debulkingQuantitative RT-PCRSerous histologyStage diseasePatient agePatient survivalDisease characteristicsDisease stageFetal growthIGF-IIThe relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer.
Lu L, Katsaros D, Wiley A, de la Longrais I, Risch HA, Puopolo M, Yu H. The relationship of insulin-like growth factor-II, insulin-like growth factor binding protein-3, and estrogen receptor-alpha expression to disease progression in epithelial ovarian cancer. Clinical Cancer Research 2006, 12: 1208-1214. PMID: 16489075, DOI: 10.1158/1078-0432.ccr-05-1801.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorDisease ProgressionEpithelial CellsEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IIMiddle AgedNeoplasm StagingOvarian NeoplasmsReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmSurvival AnalysisConceptsIGF-II expressionEstrogen receptor alpha expressionReceptor alpha expressionEpithelial ovarian cancerIGF-IIDisease progressionOvarian cancerInsulin-like growth factor (IGF) systemPrimary epithelial ovarian cancerProtein 3Insulin-like growth factorIGF signalingHigh IGF-IILarge residual lesionExpression of estrogenInsulin-like growth factor IIIGFBP-3 expressionEffects of IGFOvarian cancer treatmentGrowth factor systemFresh tumor specimensGrowth factor IIQuantitative reverse transcription PCRIGFBP-3Serous histology